You searched for Cybin - Page 22 of 60

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Signs Letter of Intent to Co-Develop Psychedelic Mushroom-Based Psilocybin Formulations

PULL signs Letter of Intent with Psyence Group to co-develop extraction techniques for production of psilocybin drug formulations Psyence is one of world’s first psychedelic mushroom companies operating a federally legal commercial cultivation and extraction facility PULL operates best-in-class processing infrastructure under Standard Processing License by Health Canada Near term milestones include Canada-based human clinical … Continue reading “Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Signs Letter of Intent to Co-Develop Psychedelic Mushroom-Based Psilocybin Formulations”

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates

Cybin has completed more than 20 pre-clinical studies in record time. Company is advancing two new therapeutic candidates with enhanced, improved properties. Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs. Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, has completed key research studies … Continue reading “Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates”

QualityStocksNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters LOI for Psilocybin Extraction, Development of Formulations

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, has inked a letter of intent (“LOI”) to form a joint venture (“JV”) with Psyence Group Inc. (CSE: PSYG). The agreement with Psyence, one of the world’s first psychedelic mushroom companies … Continue reading “QualityStocksNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters LOI for Psilocybin Extraction, Development of Formulations”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Appoints New Management Positions, Focused on Development and Clinical Operations

Cybin (NEO: CYBN) (OTCQB: CLXPF) announced changes in senior management positions. Cybin US Holdings Inc.’s new chief clinical officer will be Alexander Belser, PhD and its new chief operating officer will be Aaron Bartlone. In addition, co-founder and former COO Paul Glavine has been named chief growth officer and co-founder of Cybin Inc., while former … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Appoints New Management Positions, Focused on Development and Clinical Operations”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Enters Strategic Drug Development Agreement with Catalent Inc. (NYSE: CTLT)

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its entry into a drug development agreement with Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. According to the update, Cybin will … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Enters Strategic Drug Development Agreement with Catalent Inc. (NYSE: CTLT)”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Advances Psychedelic IND Candidates, Announces Completion of 20th Preclinical Study

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced completion of its 20th preclinical study and is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin, through collaboration with its partners and contractors, has completed key research studies both … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Advances Psychedelic IND Candidates, Announces Completion of 20th Preclinical Study”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Oppenheimer Health Care Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Oppenheimer 31st Annual Healthcare Conference. Drysdale’s presentation is scheduled to begin at 11:20 a.m. Eastern Time on Thursday, March 18, 2021. Interested parties … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Oppenheimer Health Care Conference”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at 2021 Emerging Growth Virtual Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference slated to take place from March 17-19, 2021. In addition, Drysdale will participate … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at 2021 Emerging Growth Virtual Conference”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Stifel GMP Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Stifel GMP Health Care Conference – Health Care Psychedelics: Addressing the Global Mental Health Crisis. Drysdale’s presentation is scheduled to begin at 1:00 … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Present at Stifel GMP Conference”

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Upsizes Its Bought Deal Offering Due to Surge in Demand

Cybin’s latest offering generated exceptional demand; announces upsize of “bought deal” offering Burgeoning psychedelic sector attracts investors’ attention as compound may prove effective in mental health treatments. Cybin appears set for rapid growth as research accelerates, public acceptance grows. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotech company focused on psychedelic therapeutics for various psychiatric and … Continue reading “Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Upsizes Its Bought Deal Offering Due to Surge in Demand”

Site Search

Company Search

Search Results for: Cybin